AI Article Synopsis
- The study investigated the differences in antibody levels (N-IgG) for SARS-CoV-2 between individuals who experienced COVID-19 symptoms and those who did not.
- Conducted at the National Cancer Center in Japan, the survey included 434 participants with no prior COVID-19 infections, focusing on self-reported symptoms since early 2020.
- Results showed that individuals with symptoms had significantly higher N-IgG titers, indicating possible past infections, especially in those with high fevers and multiple symptoms.
Article Abstract
This study was aimed at investigating differences in antibody titers indicative of the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between those who had experienced symptoms of coronavirus disease 2019 (COVID-19) and those who had not. We used data from a cross-sectional survey conducted at the National Cancer Center, Japan, of 434 individuals with no previous COVID-19 infection. The participants self-reported symptoms from the start of 2020. A generalized linear model was used to compare the mean SARS-CoV-2-specific IgG nucleocapsid protein (N-IgG) titer with estimated confidence intervals according to the onset of symptoms indicative of COVID-19. We observed a tendency toward an association between higher mean N-IgG titers and occurrence of high fever within the past 8 months (P = 0.053). The mean N-IgG titer was higher in those with prior symptoms (P = 0.03) and those with over three symptoms (P < 0.01) than in those without symptoms. The mean N-IgG titer was higher in those with symptoms and those with more symptoms that might indicate COVID-19 relative to those without symptoms, suggesting that transient but contained SARS-CoV-2 infection had occurred.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7883/yoken.JJID.2022.093 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vector induced humoral responses after rVSVΔG-ZEBOV-GP immunization identify vaccinated individuals and correlate with Ebola virus glycoprotein antibodies.
J Infect Dis
December 2024
Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Background: The robustness and persistence of vaccine antigen-induced antibodies are often used as proxy indicators of vaccine efficacy, but immune responses to vaccine vectors are typically less well-defined. Our study considered the kinetics of immunoglobulin (IgG) responses against the vector (vesicular stomatitis Indiana virus [VSIV]) nucleoprotein (N) and the inserted antigen (Ebola virus [EBOV]) glycoprotein (GP1,2) components of the rVSVΔG-ZEBOV-GP (rVSV-ZEBOV) vaccine and evaluated their use as biomarkers to confirm self-reported vaccination status.
Methods: From the Partnership for Research on Ebola Virus in Liberia (PREVAIL) I clinical trial (NCT02344407), we randomly selected 212 participants who received rVSV-ZEBOV (n=107) or placebo (n=105).
Immunologic mediators profile in COVID-19 convalescence.
Sci Rep
September 2024
Programa de Pós-Graduação em Biotecnologia, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil.
SARS-CoV-2 caused the pandemic situation experienced since the beginning of 2020, and many countries faced the rapid spread and severe form of the disease. Mechanisms of interaction between the virus and the host were observed during acute phase, but few data are available when related to immunity dynamics in convalescents. We conducted a longitudinal study, with 51 healthy donors and 62 COVID-19 convalescent patients, which these had a 2-month follow-up after symptoms recovery.
View Article and Find Full Text PDFComparison of Adverse Events and Antibody Responses Among Different COVID-19 Vaccination Schedules.
Viral Immunol
September 2024
Fundação Oswaldo Cruz, Eusébio, Brazil.
Global investment in developing COVID-19 vaccines has been substantial, but vaccine hesitancy has emerged due to misinformation. Concerns about adverse events, vaccine shortages, dosing confusion, mixing vaccines, and access issues contribute to hesitancy. Initially, the WHO recommended homologous vaccination (same vaccine for both doses), but evolving factors led to consideration of heterologous vaccination (different vaccines).
View Article and Find Full Text PDFClinical and serological predictors of post COVID-19 condition-findings from a Canadian prospective cohort study.
Front Public Health
May 2024
School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Introduction: More than 3 years into the pandemic, there is persisting uncertainty as to the etiology, biomarkers, and risk factors of Post COVID-19 Condition (PCC). Serological research data remain a largely untapped resource. Few studies have investigated the potential relationships between post-acute serology and PCC, while accounting for clinical covariates.
View Article and Find Full Text PDFAnti_spike and anti_nucleocapsid IgG responses to SARS-CoV-2 in children of Jordan.
Heliyon
May 2024
Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan.
Article Synopsis
- Children in Jordan show high levels of anti-S and anti-N antibodies against COVID-19, indicating strong immune responses, especially in those over 12 years old.
- A study involving 151 unvaccinated children revealed that a majority tested positive for these antibodies, with older children exhibiting higher concentrations than younger ones.
- Overall, while children's anti-S levels were found to be higher than those of naturally infected unvaccinated adults, adults had significantly greater anti-N antibody levels, suggesting different immune response dynamics across age groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!